EA201690926A1 - Цитрат железа (iii) для уменьшения сердечной недостаточности у пациентов с хроническим заболеванием почек - Google Patents

Цитрат железа (iii) для уменьшения сердечной недостаточности у пациентов с хроническим заболеванием почек

Info

Publication number
EA201690926A1
EA201690926A1 EA201690926A EA201690926A EA201690926A1 EA 201690926 A1 EA201690926 A1 EA 201690926A1 EA 201690926 A EA201690926 A EA 201690926A EA 201690926 A EA201690926 A EA 201690926A EA 201690926 A1 EA201690926 A1 EA 201690926A1
Authority
EA
Eurasian Patent Office
Prior art keywords
iron
increase
patients
iii
reduce
Prior art date
Application number
EA201690926A
Other languages
English (en)
Russian (ru)
Inventor
Энрике Порадосу
Рон Бентсур
Джеймс Ф. Оливьеро III
Original Assignee
Керикс Байофармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Керикс Байофармасьютикалз, Инк. filed Critical Керикс Байофармасьютикалз, Инк.
Publication of EA201690926A1 publication Critical patent/EA201690926A1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/26Iron; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
EA201690926A 2013-11-04 2014-11-03 Цитрат железа (iii) для уменьшения сердечной недостаточности у пациентов с хроническим заболеванием почек EA201690926A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361899866P 2013-11-04 2013-11-04
PCT/US2014/063643 WO2015066593A1 (en) 2013-11-04 2014-11-03 Ferric citrate for reducing cardiac failure in chronic kidney disease patients

Publications (1)

Publication Number Publication Date
EA201690926A1 true EA201690926A1 (ru) 2016-09-30

Family

ID=53005244

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690926A EA201690926A1 (ru) 2013-11-04 2014-11-03 Цитрат железа (iii) для уменьшения сердечной недостаточности у пациентов с хроническим заболеванием почек

Country Status (15)

Country Link
US (3) US20160256486A1 (enExample)
EP (2) EP3065734A4 (enExample)
JP (3) JP2016535780A (enExample)
KR (1) KR102392441B1 (enExample)
CN (1) CN105873583A (enExample)
AU (1) AU2014341975A1 (enExample)
BR (1) BR112016009901A8 (enExample)
CA (1) CA2928200A1 (enExample)
EA (1) EA201690926A1 (enExample)
HK (1) HK1223031A1 (enExample)
IL (1) IL245317A0 (enExample)
MX (1) MX2016005734A (enExample)
SG (1) SG11201603091QA (enExample)
TW (2) TW202203910A (enExample)
WO (1) WO2015066593A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2563819C2 (ru) 2009-07-21 2015-09-20 Керикс Байофармасьютикалз, Инк. Лекарственные формы цитрата железа (iii)
KR102633597B1 (ko) 2013-06-05 2024-02-06 트리시다, 인크. 경구 투여를 위한 양성자-결합 중합체
WO2015198304A1 (en) 2014-06-22 2015-12-30 Dexcel Pharma Technologies Ltd. Pharmaceutical compositions comprising ferric citrate and methods for the production thereof
KR20240008418A (ko) 2014-12-10 2024-01-18 트리시다, 인크. 경구 투여용 양성자-결합 폴리머
AU2017261337A1 (en) 2016-05-06 2018-11-15 Tricida, Inc. Compositions for and method of treating acid-base disorders
US11266684B2 (en) 2017-11-03 2022-03-08 Tricida, Inc. Compositions for and method of treating acid-base disorders
BR112021008142A2 (pt) 2018-10-29 2021-08-03 Pharmacosmos Holding A/S tratamento de deficiência de ferro com carboximaltose férrica
EA202191858A1 (ru) * 2019-06-12 2021-11-12 Фармакосмос Холдинг А/С Лечение дефицита железа у субъектов с риском нежелательных явлений со стороны сердечно-сосудистой системы и железо для лечения фибрилляции предсердий
TW202313072A (zh) * 2021-05-27 2023-04-01 美商凱立克斯生物製藥股份有限公司 檸檬酸鐵之兒科調配物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE351366B (enExample) * 1965-06-08 1972-11-27 Teikoku Hormone Mfg Co Ltd
US20050203169A1 (en) * 2001-08-06 2005-09-15 Moskowitz David W. Methods and compositions for treating diseases associated with excesses in ACE
US8093423B2 (en) 2003-02-19 2012-01-10 Globoasia, Llc Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
TWI335218B (en) 2003-02-19 2011-01-01 Panion & Bf Biotech Inc Ferric organic compounds, uses thereof and methods of making same
HUE025264T2 (en) 2005-08-18 2016-02-29 Panion & Bf Biotech Inc Pharmaceutical-grade ferric citrate for medical use
KR20080106506A (ko) * 2006-01-30 2008-12-08 글로보아시아 엘엘씨 만성 신장병의 치료 방법
HUE028029T2 (en) * 2006-01-30 2016-11-28 Panion & Bf Biotech Inc Method of treating chronic kidney disease
RU2563819C2 (ru) * 2009-07-21 2015-09-20 Керикс Байофармасьютикалз, Инк. Лекарственные формы цитрата железа (iii)
ES2547890T3 (es) * 2010-07-07 2015-10-09 Ardelyx, Inc. Compuestos y métodos para inhibir el transporte de fosfato
SG11201408521WA (en) * 2012-06-21 2015-01-29 Keryx Biopharmaceuticals Inc Use of ferric citrate in the treatment of chronic kidney disease patients

Also Published As

Publication number Publication date
MX2016005734A (es) 2016-11-08
AU2014341975A1 (en) 2016-05-19
HK1223031A1 (zh) 2017-07-21
SG11201603091QA (en) 2016-05-30
JP2021073230A (ja) 2021-05-13
WO2015066593A1 (en) 2015-05-07
JP2016535780A (ja) 2016-11-17
BR112016009901A8 (pt) 2020-04-14
US20190307791A1 (en) 2019-10-10
TW201609088A (zh) 2016-03-16
JP6828100B2 (ja) 2021-02-10
EP3747432A1 (en) 2020-12-09
US20250360167A1 (en) 2025-11-27
JP2019206562A (ja) 2019-12-05
EP3065734A4 (en) 2017-05-17
TWI744215B (zh) 2021-11-01
CN105873583A (zh) 2016-08-17
EP3065734A1 (en) 2016-09-14
KR102392441B1 (ko) 2022-05-02
CA2928200A1 (en) 2015-05-07
TW202203910A (zh) 2022-02-01
IL245317A0 (en) 2016-06-30
KR20160096597A (ko) 2016-08-16
US20160256486A1 (en) 2016-09-08

Similar Documents

Publication Publication Date Title
EA201690926A1 (ru) Цитрат железа (iii) для уменьшения сердечной недостаточности у пациентов с хроническим заболеванием почек
MX2014015615A (es) Uso de citrato ferrico en el tratamiento de pacientes con enfermedad renal cronica.
MX2017010734A (es) Terapia de combinacion con factores de coagulacion y anticuepos multiespecificos.
EA201890453A1 (ru) Анти-angptl8 антитела и их применение
MX2019006259A (es) Transporte para atravesar la barrera hematoencefalica.
BR112015025955A2 (pt) tratamentos anticancerosos com anticorpos anti-egfr apresentando uma baixa fucosilação
MX2020010004A (es) Composicion farmaceutica que comprende empagliflozina, metodos para tratamiento y sus usos.
PH12015502275A1 (en) Therapuetic uses of empagliflozin
EA201591762A1 (ru) Человеческие антитела к grem1
Chavez et al. New insights into the regulation of vascular permeability
MX2020011190A (es) Angiotensina ii sola o en combinacion para usarse en el tratamiento de hipotension.
EA201590883A1 (ru) Лечение помалидомидом рака у субъекта с почечной недостаточностью
PE20141577A1 (es) Espray para heridas
EA201990403A1 (ru) Человеческие анти-vegfr-2/kdr-антитела
EA201792418A1 (ru) Применение cd24 для снижения уровней холестерина липопротеинов низкой плотности
MX2015009968A (es) Metodos para tratar deficiencias de hierro con pirofosfato ferrico soluble.
EA201791611A1 (ru) Лечение пациентов детского возраста с сахарным диабетом 2 типа с помощью ликсисенатида
WO2010119991A3 (en) Anti-hgf antibody combinational cancer therapies
PH12015502301A1 (en) Microporous zirconium silicate and diuretics for the reduction of potassium and treatment of chronic kidney and/or chronic heart disease
EA202090028A1 (ru) Способы уменьшения или предотвращения сердечно-сосудистых явлений у пациентов с сахарным диабетом ii типа
UA86387U (ru) Способ оценки эффективности лечения больных с артериальной гипертензией, объединенной с метаболическим синдромом
UA62757U (ru) Способ прогнозирования адекватности программного гемодиализа у больных с хронической болезнью почек v стадии
EA201790790A1 (ru) Антитела человека против vegfr-2/kdr
BR112014032781A2 (pt) dispositivo para aumentar fluxo sanguíneo, perfusão tecidual e distribuição de fluidos por estimulação neuromuscular em cavalos e outros mamíferos não-humanos
Chalone T. RYTÖMAA